Programmed cell death ligand 1 expression and clinical correlation in epithelial ovarian carcinoma patients

Phase 1

Recruiting

• Conditions: Epithelial Ovarian Carcinoma patients; Ovary, Carcinoma, Prognosis, PDL1

• Registration Number: TCTR20161115004
• Lead Sponsor: Siriraj Research Development Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-11-15
• Study Completion: 2017-11-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 92

Inclusion Criteria

•Patients who are suspected Ovarian cancer and admit for primary surgical treatment
•Age ≥ 18 years and can use Thai and sign in consent form

Exclusion Criteria

Final pathology is not epithelial ovarian carcinoma

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prevalence of PDL1 expression in EOC 1 year rate in percent

Secondary Outcome Measures

Name	Time	Method
Correlation of Immunohistochemistry and mRNA expression 1.5 year Logistic Regression Analysis